Category: Press Release

This category covers all news related Press Release

Posted on

New generative AI-powered Zoom IQ features are now available to Zoom users via free trials

Zoom IQ meeting summary and chat compose features allow users to quickly summarize Zoom Meetings without recording and draft content in Zoom Team Chat

SAN JOSE, Calif., June 05, 2023 (GLOBE NEWSWIRE) — Today Zoom Video Communications, Inc. (NASDAQ: ZM) launched key features of Zoom IQ, a smart companion that empowers collaboration and unlocks people’s potential through generative AI. Now available through free trials for customers in select plans,1 the Zoom Meeting summary and Zoom Team Chat compose features will help teams improve productivity, balance workday priorities, and collaborate more effectively.

“With the introduction of these new capabilities in Zoom IQ, an incredible generative AI assistant, teams can further enhance their productivity for everyday tasks, freeing up more time for creative work and expanding collaboration,” said Smita Hashim, chief product officer at Zoom. “There is no one-size-fits-all approach to large language models, and with Zoom’s federated approach to AI, we are able to bring powerful capabilities to our customers and users through Zoom’s own models as well as our partners’ models.”

Zoom’s federated approach to AI leverages its own proprietary large language AI models, those from leading AI companies — such as OpenAI and Anthropic — and select customers’ own models. With this flexibility to incorporate multiple types of models, Zoom’s goal is to provide the most value for its customers’ diverse needs.

The first set of Zoom IQ capabilities is now generally available to Zoom customers in select plans as free trials:

  • Meeting summary: Zoom Meeting hosts can now create a summary powered by Zoom’s own large language models and share it via Zoom Team Chat and email without recording the conversation. Hosts receive automated summaries and can share them with attendees and those who didn’t attend to improve team collaboration and speed up productivity.
  • Chat compose: Zoom Team Chat users can now use the generative AI-powered compose feature, which leverages OpenAI’s technology, to draft messages based on the context of a Team Chat thread in addition to changing message tone and length as well as rephrasing responses to customize text recommendations.

Zoom is committed to empowering customers with the tools they need to control their data. In order to use these features, customers will need to go to the Zoom admin console and opt into the free trials for each feature. As part of the opt-in, customers will also select data-sharing options with Zoom. Account admins may change this data-sharing selection at any time. Customer data will not be used to train third-party models. More information can be found here.

To further help its customers and users, Zoom will continue to enhance its products with Zoom IQ capabilities. The next set of generative AI-powered features, scheduled to be released soon, will allow users to draft email content, summarize Team Chat threads, organize ideas, and draft whiteboard content:

  • Email compose: Harnessing the power of generative AI, users will get email draft suggestions in response to the conversational context from prior Zoom Meetings, Zoom Phone calls, and email threads. Initially available in Zoom IQ for Sales, sales professionals will be able to quickly follow up with customers based on the context of their last conversation. Email compose will be generally available in the coming weeks.
  • Zoom Team Chat thread summaries: Ever step away from the computer only to come back to a flurry of Team Chat messages? Available in the coming months, Team Chat thread summaries will allow users to catch up with the click of a button.
  • Meeting queries: Joining a Zoom Meeting late can be both disruptive and confusing for the latecomer, but not anymore. Meeting queries will allow users to catch up quickly without disrupting the meeting flow by discreetly submitting a query via the in-meeting chat and receiving a generative AI-created summary of what they missed. The meeting queries feature is expected to be generally available in the coming months.
  • Whiteboard draft: Who hasn’t experienced the “cold start” problem? A slow start to a brainstorming session can put a damper on idea generation, but with whiteboard draft, teams will be able to get a set of initial ideas, simply using text prompts. The whiteboard draft feature is expected to be generally available in the coming months.
  • Whiteboard synthesize: Brainstorming sessions typically end with a lot of ideas that need to be organized in order to execute. The whiteboard synthesize feature automatically organizes ideas into categories, so teams can get to work faster. This feature is expected to be generally available in the coming months.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Lacretia Taylor
press@zoom.us

__________________________
1 Meeting summary and chat compose with Zoom IQ are currently available in English only to Zoom One packages (Enterprise Plus, Enterprise, Business Plus, Business, Pro) and select Zoom legacy bundles (Enterprise Named Host, Enterprise Active Host, Zoom Meetings Enterprise, Zoom Meetings Business, Zoom Meetings Pro) — as free trials for a limited time. Select verticals and geos may be excluded.

Free trial features may be discontinued or modified at any time and may be subject to usage limits, regional or license restrictions, and other terms and conditions.

GlobeNewswire Distribution ID 8852345

Posted on

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101

  • NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets
  • Lotus Pharmaceuticals will acquire worldwide rights for NRX-101 for S-TRBD and will be responsible for commercialization of NRX-101 in markets outside the US through Lotus’s direct presence in certain Asian markets or through their export division, which currently has partnerships in numerous markets, including in Europe, Japan, China, Australia and Latin America
  • Alvogen, through its CNS focused Almatica® division, will be responsible for U.S. commercialization of NRX-101
  • NRx will be eligible to receive up to $330 million in milestone payments tied to development progress and sales targets as well as tiered double-digit escalating to the mid-teens royalty payments contingent upon certain sales thresholds in the U.S. and a fixed royalty payment for markets outside the U.S.
  • Agreement includes a right of first negotiation for new indications outside of the field of bipolar depression with suicidality for NRX-101 and/or potential new products containing D-cycloserine in combination with an antidepressant / antipsychotic

RADNOR, Pa. and MORRISTOWN, N.J. and TAIPEI, Taiwan, June 05, 2023 (GLOBE NEWSWIRE) — Lotus Pharmaceuticals (1795:TT; “Lotus”), a multinational pharmaceutical company, Alvogen, a privately owned U.S. based pharmaceuticals company, and NRx Pharmaceuticals Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals or NRx”), a clinical stage biopharmaceutical company, today announced a global collaboration agreement covering the development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets.

Under the terms of the agreement, relating to NRX-101 for the U.S. market, NRx is entitled to receive an initial payment of $10 million upon achieving both a successful read-out from the ongoing Phase 2b/3 clinical trial in S-TRB and completion of a Type B meeting with the U.S. Food and Drug Administration (FDA). NRx would receive an additional payment of $5 million upon receipt of FDA approval for NRX-101 as well as bonus milestone payments of increasing amounts up to $330 million based on reaching certain net sales targets. In addition to success-based payments, NRx is eligible to receive a royalty on net sales between 12% and 16% contingent on certain sales thresholds for the U.S. market and other success-based payments for markets outside of the U.S.

Lotus will acquire worldwide rights for NRX-101 for treatment of S-TRBD and will be responsible for commercialization of NRX-101 in markets outside of the U.S. through their direct commercial presence in certain Asian markets or through Lotus’s export division where the company currently markets an extensive portfolio of products through top-tier partners. Lotus will partner with Alvogen, a longstanding partner for Lotus in the U.S., to commercialize NRX-101 for treatment of S-TRBD in the U.S. market through Alvogen’s Almatica label. Almatica is the CNS-focused division of Alvogen that currently markets six branded products. Alvogen and Lotus have committed to fund the next registrational study in suicidal treatment-resistant bipolar depression to support approval of NRX-101 contingent upon successful results of the ongoing Phase 2b/3 clinical trial and completion of a Type B meeting with the FDA. Lotus and Alvogen will have a right of first negotiation for new indications outside of the field of bipolar depression with suicidality for NRX-101 and/or potential new products containing D-cycloserine in combination with an antidepressant / antipsychotic.

Stephan Willard, J.D., Chief Executive Officer of NRx, commented, “This collaboration can accelerate the delivery of NRX-101 to patients grappling with suicidal bipolar depression who desperately need better treatment alternatives. With our current resources we believe we can fund our operations until the expected Phase 2b/3 trial data. This global partnership significantly minimizes the need for future capital raises for NRX-101 development and commercialization. Alvogen and Lotus, with their CNS expertise and global operational capabilities, are ideal partners for this and possibly other NRx programs.”

Lisa Graver, Chief Executive Officer of Alvogen, commented, “A medication that improves depression in bipolar patients with elevated risk of suicide would represent a significant improvement in treatment, and we view the Phase 2 STABIL-B data of NRX-101 as promising to that effect. This agreement is congruent with our strategy of developing branded CNS products with clear differentiation and patient benefit while leveraging our proven commercialization capabilities under our Almatica brand. NRX-101 provides an excellent addition to our growing CNS pipeline.”

Petar Vazharov, Chief Executive Officer of Lotus, commented, “This is an exciting transaction for Lotus. Over much of the last decade, Lotus has been able to transition itself from a domestic generics Taiwanese company into a global pharma company that exports its intellectual property all over the world through either our direct presence across Asia or through our export business that includes the U.S., Japan, China, Latin America and Europe. The addition of NRX-101 to our pipeline is completely in-line with our strategic objective to drive heightened innovation that addresses significant unmet medical needs.”

An estimated seven million people are living with bipolar depression in the U.S. alone1. The risk of suicide within the group is very high, with data indicating that 50% or more of these patients will attempt suicide in their lifetime2. There are currently no medications specifically approved for people with bipolar depression and elevated levels of suicidality. NRX-101 is the first investigational medication to be specifically studied in this vulnerable patient population. Proof-of-concept data from the Phase 2 STABIL clinical trial, in which patients with bipolar depression and acute suicidality were randomized to NRX-101 or lurasidone after stabilization with one infusion of ketamine, showed a statistically significant benefit of NRX-101 vs lurasidone. Based on these data, the U.S. FDA granted Breakthrough Therapy Designation (BTD) and a Special Protocol Assessment (SPA) for NRX-101 in bipolar depression with acute suicidality.

NRx Pharma recently announced that it has upgraded and expanded its ongoing Phase 2 randomized, controlled clinical trial in bipolar depression with sub-acute suicidality to a registrational Phase 2b/3 clinical trial.   Results from the ongoing Phase 2b/3 clinical trial are expected by year-end 2023. NRx will be hosting a conference call to discuss in greater detail the impact of the transaction.

About NRX-101

Up to 50% of individuals with bipolar disorder attempt suicide over their lifetime, and estimates indicate that up to 20% may succumb to suicide3. The only FDA-approved treatment for patients with treatment-resistant suicidal bipolar depression remains electroconvulsive therapy.

Conventional antidepressants can increase the risk of suicide in certain patients; hence their labels contain a warning to that effect. NRX-101 is a patented, oral, fixed dose combination of D-cycloserine and lurasidone, neither of which has shown addiction potential in preclinical models. Based on the results of a Phase 2 proof-of-concept study, NRX-101 received Breakthrough Therapy Designation from the FDA for the treatment of severe bipolar depression in patients with Acute Suicidal Ideation & Behavior (ASIB) after initial stabilization with ketamine or other effective therapy.

NRX-101 is one of the first oral antidepressants currently in late-stage clinical studies targeting the NMDA-receptor in the brain, which represents potentially a key new mechanism to treat depression with and without suicidality, as well as PTSD and other indications. To date, NRX-101 is the only oral NMDA investigational medicine focused on bipolar depression in patients with acute and sub-acute suicidality.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically bipolar depression with suicidality and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain’s N-methyl-D-aspartate (NMDA) receptor and is being investigated in a Phase 2b/3 clinical trial for Suicidal Treatment-Resistant Bipolar Depression, which includes patients with both acute and sub-acute suicidality, an indication for which the only approved treatment is electroshock therapy. The company’s prior Phase 2 STABIL-B clinical trial evaluating NRX-101 in patients with Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB) demonstrated a substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine. Based on the findings from the STABIL-B trial, the U.S. Food and Drug Administration (FDA) granted a Special Protocol Agreement and Breakthrough Therapy Designation for NRX-101 in patients with Severe Bipolar Depression with ASIB.

About Alvogen and Almatica

Alvogen is a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products for the US market. The company has a diverse portfolio and pipeline that includes both branded and generic products across various administration forms. The Alvogen-family of companies includes Alvogen US (Generics), Almatica (Brands) and Almaject (Injectables).

Almatica Pharma LLC is a wholly owned subsidiary of Alvogen, Inc. and is a U.S. pharmaceutical company focused on the development, acquisition and commercialization of branded pharmaceutical products. Its current product portfolio covers a range of therapeutic areas, but promotional focus is on central nervous system disorders and conditions.

About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.

1Merikangas, K., et al.(2007). Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 64:543-552

2Pallaskorpi, et al. Incidence and Predictors of suicide attempts in bipolar I and II disorder: A 5-year follow-up study, Bipolar Disorders, 2016

3Psychiatric Times; Suicide Attempts and Completions in Patients with Bipolar Disorder

NRX Cautionary Note Regarding Forward-Looking Statements

This announcement of NRx Pharmaceuticals, Inc. includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company’s strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company’s management.

The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.

Lotus Cautionary Note Regarding Forward-Looking Statements

Except for historical information contained herein, the matters set forth in this document are forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are not based on historical facts but rather on management’s expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities. Statements in this presentation about our future plans and intentions, results, level of activities, performance, goals or achievements or other future events constitute forward looking statements. Wherever possible, words such as “anticipate”, “believe”, “expect”, “may”, “could”, “will”, “potential”, “intend”, “estimate”, “should”, “plan”, “predict”, or the negative or other variations of statements reflect management’s current beliefs and assumptions and are based on the information currently available to our management. Investors are cautioned not to place undue reliance on these forward-looking statements, which are made as of the date of this document and we assume no obligation to update or revise any forward-looking statements.

Lotus Contacts:

INVESTOR AND MEDIA RELATIONS
Susan Liao, Head of Investor Relations
+886 2 2700 5908
investor@lotuspharm.com

NRX Contacts:

CORPORATE CONTACT
Matthew Duffy
Chief Business Officer
mduffy@nrxpharma.com

INVESTOR RELATIONS
Suzanne Messere
Investor Relations
suzanne.messere@sternir.com

Alvogen Contacts:

Andrea Sweet
andrea.sweet@alvogen.com

GlobeNewswire Distribution ID 1000823518

Posted on

VERSES, DENTONS US and SPATIAL WEB FOUNDATION To Release Industry Report Titled “A Path to Global AI Governance”

Figure 1

The Road to Autonomy – Executive Summary

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) — VERSES AI Inc.  (CBOE CANADA:VERS) (OTCQX:VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in the next generation of artificial intelligence (“AI”), announces the release on June 8, 2023 of an AI industry report titled “THE ROAD TO AUTONOMY: A Path To Global AI Governance”.

The report combines the legislative expertise from Dentons, the world’s largest multinational law firm, and the AI acumen of VERSES with the guidance on technical standards from the Spatial Web Foundation to provide an in-depth analysis of the legal and key legislative trends from across the world on the state of AI regulation and recommendations for a path forward for government regulation of AI.

The report aspires to pioneer a fresh approach for legal practitioners, government regulators, and lawmakers, to keep pace with the rapid technological advancements and to guide their adaptation. The critical aspect of the report is to promote the adoption of standards for what VERSES considers “law as code.” The objective is to encode laws and legal principles into an understandable, machine-readable language that will facilitate the comprehension and autonomous compliance of AI systems with legal frameworks and social norms.

The report analyzes the unprecedented challenges presented by the emergence of AI and autonomous software, devices, and vehicles addressing fundamental questions like, “How can governments regulate AI systems that are on a path to regulating themselves? How can humans stay in the loop to ensure AI alignment with human values, principles, and laws, while guaranteeing fair and equitable services for all individuals and communities? And, how do we encode and enforce AI laws directly in AI systems themselves?”

The report critically examines the transformative power of rapidly evolving technologies such as AI systems and their impending impact on legal, regulatory, and government sectors and accentuates the crucial need for developing and adopting standards that foster the understanding, governance, and interoperability of AI and autonomous systems. The report underscores the role of these technical standards in shaping dynamic and effective laws to regulate, oversee, and contemporize AI activities.

The goal of the report is to provide governments, regulators, and legislators with a pragmatic framework that not only informs but also provides a roadmap for policymaking, legislation, and compliance efforts in the field of AI. This is relevant to the flourishing autonomous vehicle industry, while also serving as a fundamental guide for all future AI-driven systems. Emphasizing the urgency of a globally unified, forward-thinking approach to AI governance, the report signals the vital need for standards development and deployment as the world navigates the pathway to Autonomous Intelligent Systems (“AIS”).

Significantly, the report points to the instrumental role of sociotechnical standards, as demonstrated by the work of the Institute of Electrical And Electronics Engineers IEEE P2874 Working Group. This initiative from the world’s largest association of technical professionals, underscores the importance of aligning AIS with human values and reducing the risk of harmful behavior.

The report also highlights the European Commission’s Flying Forward 2020 (“FF2020”) project for successfully implementing these standards. Led by VERSES and running on its KOSM platform, the FF2020 project featured autonomous AI-powered drones executing various tasks, such as medical supply delivery, building security inspection, and large crowd monitoring, all while adhering to local laws. The project exemplifies how the seamless integration of standards for AI with Urban Air Mobility and current legal and regulatory frameworks could improve the implementation of AI-powered services at city scale and beyond.

The report envisions the application of these standards to a host of sectors, including healthcare, education, finance, supply chain and more, paving the way for a smarter world with AI seamlessly operating behind the scenes.

“AI is advancing at an unprecedented pace, raising concerns about the direction of its future trajectory. As AI evolves towards autonomous systems, the need for regulation becomes critical. We must address the challenge of regulating self-regulating AI to ensure alignment with human values and prevent potential risks. By implementing global technical standards and establishing an international AI regulatory framework, we can harness the immense benefits of AI while safeguarding against its potential perils,” stated VERSES CEO, Gabriel René.

“We are thrilled to collaborate with VERSES, as the challenge of regulating machines raises the question of how to strike a balance between control and freedom for entities incapable of comprehending laws or guiding principles. The current pace of the legal system hinders effective regulation and allows unchecked development of rapidly evolving technologies like AI. A new socio-technological standards-based approach seems to be a very pragmatic and appealing way forward,” said Peter Stockberger, Partner at Dentons US.

In summary, the report calls for a safe, effective, and inclusive journey down the “Road to Autonomy,” ensuring that future AI systems are not just technically advanced but also aligned with the best interests of humanity, both now and in the future. With AI influencing every sector, this insightful report offers pragmatic recommendations for a more secure, innovative, and integrated AI-driven future. The full report will be available on the VERSES, DENTONS, and Spatialweb.org websites on or around June 8, 2023, with the executive summary already available for preview.

About VERSES

VERSES is a cognitive computing company specializing in next-generation AI. Modeled after natural systems and the design principles of the human brain and the human experience, VERSES flagship offering, GIA™, is an Intelligent Assistant for everyone powered by KOSMOS™, a network operating system enabling distributed intelligence.  Built on open standards, KOSM transforms disparate data into knowledge models that foster trustworthy collaboration between humans, machines, and AI, across digital and physical domains. Imagine a smarter world that elevates human potential through innovations inspired by nature. Learn more at VERSES, LinkedIn, and Twitter.

About Dentons 
Dentons is designed to be different. As the world’s largest global law firm with 21,000 professionals in over 200 locations in more than 80 countries, Denton’s can help you grow, protect, operate and finance your business. Denton’s polycentric and purpose-driven approach, together with their commitment to inclusion, diversity, equity and ESG, ensures they challenge the status quo to stay focused on what matters most to you. www.dentons.com

About the Spatial Web Foundation 
The Spatial Web Foundation is a non-profit organization dedicated to the development and ethical use of technology, specifically in the creation and implementation of the Spatial Web protocol. The foundation’s core initiatives include developing open standards and protocols, promoting interoperability, and educating the public and policymakers. The foundation supports transparency and accountability in the development and use of technology, promotes responsible innovation, engages in dialogue and collaboration with various stakeholders, and adopts a proactive approach to addressing emerging ethical challenges. Ultimately, the Spatial Web Foundation seeks to create a more inclusive, accessible, and equitable internet that empowers individuals and communities to connect, create, and thrive.

On Behalf of the Company 

Gabriel René
VERSES Technologies Inc.
Co-Founder & CEO
press@verses.io

Media and Investor Relations Inquiries 

Leo Karabelas
Focus Communications
President
info@fcir.ca
416-543-3120

The NEO has not reviewed or approved this press release for the adequacy or accuracy of its contents.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1df22be2-a8db-4ce3-8217-05fbc905429f

GlobeNewswire Distribution ID 8852013

Posted on

SHAKA ILEMBE IS READY TO HIT GLOBAL SCREENS!

Johannesburg, June 02, 2023 (GLOBE NEWSWIRE) —
  • MultiChoice Group, the largest producer of original content on the African continent, is set to debut SHAKA ILEMBE, its biggest ever primetime-drama series.
  • Created by the award-winning South African Emmy and Oscar nominated team at Bomb Productions, with global star Nomzamo Mbatha taking on double billing as lead actress and Executive Producer.

The Johannesburg Stock Exchange listed MultiChoice Group is about to debut it’s biggest ever prime-time drama series, Shaka Ilembe, an epic 12-part tale that follows the origins story of the legendary African monarch and military strategist, King Shaka. Six years in the making, the highly anticipated series boasts the talents of some of South Africa’s biggest stars, including Coming 2 America lead actress Nomzamo Mbatha.

With the epic series launching across sub-Saharan Africa on MultiChoice’s video entertainment service DStv this June, Shaka Ilembe is already attracting significant interest outside of the continent. MultiChoice Studios, the busy sales and distribution arm of the sub-Saharan business, is hard at work introducing the title to international buyers at film markets from Cannes to Los Angeles, building on a growing MultiChoice slate of original production exports including the Emmy nominated Reyka and the Deon Meyer penned Trackers.

For Nomsa Philiso, CEO of MultiChoice General Entertainment, Shaka Ilembe offers audiences worldwide the opportunity to immerse into a rich dynastic African story, set in the 1700’s.

“We are confident that this series will travel. It speaks, not only the heritage of the Zulu Nation, but to the fascination that the world has always had with King Shaka. It speaks to Africans owning the stories that their ancestors lived. And it celebrates that, long before colonialism, beyond the pages of history, there was a majestic ancient era of African Kings and Queens, warriors, healers, and leaders who lived, loved, ruled, battled, and above all, entrenched a legacy and culture that endures even today. Further, the series was filmed in isiZulu so it carries a distinct language identity, but it will be sub-titled in multiple languages so audiences from across the globe can enjoy it.”

Central to the Shaka Ilembe story is actress Nomzamo Mbatha, who balances her Executive Producer responsibilities with fulfilling a life-long ambition to play King Shaka’s beloved mother, Queen Nandi.

Speaking to her dual roles on Shaka Ilembe, Mbatha says, “This series is rich in depth, and was shot in 4K on a tremendous scale that fuels the narrative. From the fierce battlefield choreography and the meticulous accuracy of the wardrobe to the resonance of the script, it’s remarkable. And while this is a fictional story, it’s inspired by real events, people, and places. Already, ahead of our domestic launch audiences at home are very supportive because, they know like I do, that TV series like Shaka Ilembe transcends entertainment, and delivers representation, diversity, and progress.”

Mbatha leads off a top-flight ensemble cast featuring some of the country’s most charismatic leading men – Lemogang Tsipa, Senzo Radebe, Wiseman Mncube, Thembinkosi Mthembu and Mondli Makhoba alongside powerful character actresses Khabonina Qubeka, Sthandiwe Kgoroge, Dawn Thandeka King and rising star Hope Mbhele. Meanwhile, playing the boy destined to be King, is gifted young newcomer Ntando Zondi whose prodigious talent was unearthed during the filming of the series.

Filmed in South Africa, SHAKA ILEMBE features much of the country’s magnificent wildlife and scenery, including the mountains, savanna, and coastline of the lushly beautiful province of KwaZulu Natal, home to the majority of South Africa’s Zulu people. Key filming locations here included the towns of Eshowe, Nkandla Forest, Port Edward, Drakensburg, Mooi River and Zulu Falls.

Meanwhile other parts of the series were shot on a purpose-built backlot near the UNESCO World Heritage Site “The Cradle of Humankind” where Emmy and Academy nominated showrunners Bomb Productions hosted the King of the Zulu Nation, His Excellency Misuzulu kaZwelithini, during a special visit to the set for the Royal to see first-hand the level of detail and care that was employed to ensure that the authenticity of the set.

For Mauro Black, MultiChoice Studios Content, Sales, and Distributions Director, it is this credibility of intention and execution that makes SHAKA ILEMBE a powerful cultural export.

“International buyers are discerning about what they will bring their local audiences from the global TV marketplace. So, from inception, SHAKA ILEMBE was crafted to weld an immense depth of oral, written and illustrated Zulu history into the framework of a highly watchable prime-time drama. The result is a deeply meaningful but profoundly enjoyable title that should win fans in markets as diverse as Africa, the Caribbean, Europe, Asia, and the Americas.”

With over 8000 people contributing their skills to create Shaka Ilembe, the series has already won the support of five of South Africa’s biggest brands (Telkom, LottoStar, Grant’s Whisky, Toyota SA and Santam) who all signed on as commercial partners within days of seeing an extended preview of the series.  In addition, it’s Academy Award and BAFTA nominated Creative Director Angus Gibson and Sundance winning Executive Producer Desiree Markgraaff have drawn from the best of South Africa’s talent, including acclaimed Zulu musician Mbuso Khoza whose skill and vision drives the series soundtrack.

Attachment

Elizabeth Ferreira 
MultiChoice Group Ltd
+27834825241
elizabeth.fourie@multichoice.co.za

GlobeNewswire Distribution ID 8851223

Posted on

GWGHQ FINAL DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages GWG Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GWGHQ

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of GWG Holdings, Inc. L Bonds or Preferred Stock of GWG (“GWG securities”) (OTC: GWGHQ) between December 23, 2017 and April 20, 2022, both dates inclusive (the “Class Period”), of the important June 2, 2023 lead plaintiff deadline.

SO WHAT: If you purchased GWG securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the GWG class action, go to https://rosenlegal.com/submit-form/?case_id=14048 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 2, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) they intended to misappropriate GWG assets; (2) GWG’s life insurance investment business had failed; and (3) GWG could only repay prior investors by issuing increasing amounts of securities to new investors. In essence, defendants had turned GWG into a Ponzi scheme. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the GWG class action, go to https://rosenlegal.com/submit-form/?case_id=14048 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8850788

Posted on

MPW FINAL DEADLINE NOTICE: GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Medical Properties Trust, Inc. Investors with Losses Over $100K to Secure Counsel Before Important June 12 Deadline in Securities Class Action – MPW

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Medical Properties Trust, Inc. (“MPT”) (NYSE: MPW) between July 15, 2019 and February 22, 2023, both dates inclusive (the “Class Period”), of the important June 12, 2023 lead plaintiff deadline.

SO WHAT: If you purchased MPT securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the MPT class action, go to https://rosenlegal.com/submit-form/?case_id=12794 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 12, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false or misleading statements and/or failed to disclose that: (1) the Company masked the distressed state of its tenants through sale-leaseback arrangements which were essentially round-robin transactions in that they allowed debt-saddled tenants to meet their obligations in the short-term; (2) the Company fraudulently transferred hundreds of millions of dollars in what amounted to a bailout of financially distressed tenants; (3) the Company concealed its fraudulent transfers with fake construction projects with purportedly high capital expenses, despite the fact that the Company entered into “triple-net leases,” which meant that its tenants were obligated to pay a significant portion of expenses, such as real estate taxes, insurance, and maintenance; and (4) as a result, the Company’s public statements, including those with respect to the Pennsylvania Properties, were materially false and misleading at the time they were made. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the MPT class action, go to https://rosenlegal.com/submit-form/?case_id=12794 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8850780